Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The Boston Beer Company entered into a Rule 10b5-1 trading plan to repurchase up to $37.5 million of its Class A Common Stock. The buyback program is scheduled to run from December 28, 2026, through March 26, 2027.
High Roller Technologies reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared to a net loss of $0.2 million in the prior year period. Revenues decreased significantly from $15.8 million to $8.6 million year-over-year, while the company successfully completed an offering that increased cash and cash equivalents to $13.4 million.
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.65M of Stock
Japan Post Holdings Co. Ltd. sold 13,000 shares of Aflac Inc at $126.01 to $126.97 a share (average $126.63) in 2 transactions, worth $1.65M in total on Nov 11, 2026. Shares held after the trade: 50,108,329 (-0.0%).
Vistance Networks Director Timothy T. Yates Buys $98.7K of Stock
Timothy T. Yates, Director, bought 25,000 shares of Vistance Networks, Inc. at $3.95 a share, worth $98.7K in total on Nov 12, 2026. Shares held after the trade: 248,751 (+11.2%).
Carlyle Credit Solutions reported total investment income of $66.7 million for the quarter ended September 30, 2026, and net investment income of $38.3 million. Total net assets decreased slightly to $1.74 billion from $1.77 billion at year-end 2025, primarily driven by $51.7 million in net unrealized depreciation on investments and $129.7 million in distributions to stockholders.
Worthington Enterprises hosted an Investor and Analyst Day on November 10, 2026, to discuss its standalone strategy and performance since its separation from the steel processing business. The company introduced updated long-term financial targets and detailed growth opportunities across its Building Performance Solutions and Trade & Specialty Solutions segments.
AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.
TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.
Term
Q3 2026
“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”
Johnston Erwin, Chief Executive Officer of TRexBio
“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
Johnston Erwin, Chief Executive Officer of TRexBio
IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.
Propanc Biopharma reported a net loss of $8.6 million for the quarter ended September 30, 2026, compared to a $4.8 million loss in the prior year, driven largely by a significant increase in compensation and professional expenses. The company's cash position decreased to $258,366 from $832,006 at the start of the fiscal year, though it raised $2 million through the exercise of Series C warrants.
Air Industries Group reported a significant turnaround in the third quarter of 2026, with net sales increasing to $14.6 million and net income reaching $946,000 compared to a loss in the prior year period. However, for the nine months ended September 30, 2026, the company still recorded a net loss of $920,000 despite a 8.7% increase in year-to-date net sales.
Axos Financial held its 2026 Annual Meeting of Stockholders on November 12, 2026, with 87.81% of eligible shares represented. Stockholders elected three Class I directors (Tamara N. Bohlig, Nicholas A. Mosich, and Edward J. Ratinoff), approved executive compensation in an advisory vote, and ratified BDO USA, P.C. as the independent auditor for fiscal year 2027.
Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.
Invesco Real Estate Income Trust Inc. (INREIT) provided its monthly update for October 31, 2026, reporting a total Net Asset Value (NAV) of approximately $670.2 million. The company disclosed NAV per share across multiple share classes, ranging from $26.06 for Class T to $28.48 for Class E, which will serve as the transaction price for December 1, 2026. The filing details the trust's portfolio composition, including $1.15 billion in real estate investments offset by $480 million in mortgage notes and credit facilities.
Frontdoor CEO William C. Cobb Sells $20.4M of Stock
William C. Cobb, CEO, sold 208,747 shares of Frontdoor, Inc. at $96.69 to $99.17 a share (average $97.67) in 3 transactions, worth $20.4M in total between Nov 10, 2026 and Nov 12, 2026. Shares held after the trade: 184,335 (-34.3%).
Elicio Therapeutics held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected three Class III directors (Julian Adams, Jay R. Venkatesan, and Carol Ashe) to three-year terms and ratified Baker Tilly US, LLP as the company's independent auditor for the fiscal year ending December 31, 2026.
Siebert Financial Corp. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a net income of $5.6 million in the prior year period. While total revenue grew to $79.3 million, expenses surged to $83.7 million, driven by higher employee compensation, technology costs, and one-time settlement and impairment charges.
SilverBox Corp IV reported a net income of $3.64 million for the nine months ended September 30, 2026, primarily driven by $4.77 million in interest earned on trust account investments. During the period, the company experienced significant redemptions, with $207.5 million withdrawn from the Trust Account, leaving $10.64 million in investments remaining.
BioKey (Cayman), Inc. reported zero revenue for the nine months ended September 30, 2026, with a net loss of $873,721 compared to $538,188 in the prior year period. The company remains heavily dependent on recurring loans from ABVC BioPharma, Inc. to support its operations, with total liabilities reaching $7.56 million against total assets of $1.61 million.
Arrive AI Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven largely by a $12.3 million loss on the conversion of notes. Total assets decreased to $9.2 million from $10.9 million at year-end 2025, while the company maintained a stockholders' equity of $2.2 million.
Planet Green Holdings Corp. reported a significant increase in net revenues to $9.58 million for the nine months ended September 30, 2026, compared to $67,270 in the prior year, though it still incurred a net loss of $1.04 million. The company's balance sheet shows a total stockholders' deficit of $3.06 million, and it continues to manage significant liabilities from discontinued operations.
CNO Financial Group entered into a Sixth Amended and Restated Section 382 Rights Agreement to extend its existing 'poison pill' through November 13, 2029. The agreement is designed to protect the company's tax net operating loss carryforwards by deterring any person from acquiring 4.99% or more of the company's outstanding common stock without board approval.
Appian Insider Mark Steven Lynch Sells $507K of Stock
Mark Steven Lynch sold 9,533 shares of Appian Corp at $53.14 a share, worth $507K in total on Nov 11, 2026. Shares held after the trade: 37,981 (-20.1%).
Sensata Technologies Holding EVP, Chief HR Officer Lynne J. Caljouw Sells $309K of Stock
Lynne J. Caljouw, EVP, Chief HR Officer, sold 7,726 shares of Sensata Technologies Holding plc at $40.02 a share, worth $309K in total on Nov 10, 2026. Shares held after the trade: 58,679 (-11.6%).
Moderna's Chief Legal Officer, Shannon Thyme Klinger, will retire from the company effective March 31, 2027. Under a transitional services agreement, she will receive $1.63 million in severance plus potential performance bonuses of up to $8 million tied to the outcomes of ongoing litigation with Arbutus, Genevant, Pfizer, and BioNTech.
CCS IX Portfolio Holdings, LLC reported a significant increase in total investment income to $58.6 million for the nine months ended September 30, 2026, compared to $18.5 million in the prior year period. Net assets grew to $732.4 million, driven by $353.3 million in capital contributions and $31.6 million in net increase in net assets from operations.
Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.
aTyr Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously been under a deficiency notice since December 2025 and was granted an extension until November 30, 2026, to meet the standard. As of this filing, the company has no outstanding deficiency notices from Nasdaq.
Saga Communications reported a net loss of $7.1 million for the third quarter of 2026, primarily driven by a $9.2 million impairment of intangible assets. Net operating revenue decreased to $26.7 million from $28.2 million in the prior year period, while total assets declined to $183.0 million as of September 30, 2026.